Genfit S.A. (GNFT)
Price:
5.86 USD
( + 0.17 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
NEWS
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
globenewswire.com
2025-12-10 12:00:00Données préliminaires très encourageantes de l'étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter: Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d'une troisième cohorte de patientsLa combinaison GNS561MEKi a démontré une stabilisation de la maladie chez tous les patients évaluables, avec des signes de réduction tumorale dans un sous-groupe de patients, justifiant la poursuite de l'investigationDoses recommandées pour la Phase 2 attendues au premier semestre 2026 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), le 10 décembre 2025 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui des données préliminaires de Phase 1b encourageantes issues de son essai clinique évaluant GNS561 en combinaison dans le CCA.
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
globenewswire.com
2025-12-10 12:00:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today reports encouraging preliminary Phase 1b data from its CCA clinical trial evaluating GNS561 in combination.
GENFIT Announces Appointment of new Chief Medical Officer
globenewswire.com
2025-11-27 12:00:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT's clinical development plans and lead the Clinical (Operations and Strategy), Biometrics and Pharmacovigilance teams.
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
globenewswire.com
2025-11-20 12:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update.
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
globenewswire.com
2025-11-20 12:00:00GENFIT announces the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
globenewswire.com
2025-11-10 01:45:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Failure (ACLF) research via exosome-based regenerative technology.
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
globenewswire.com
2025-11-10 01:30:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a novel formulation, investigational drug G1090N, which serves as the cornerstone of our ACLF pipeline and reflects our commitment to addressing critical unmet needs in liver disease. G1090N was designed to optimize dose-response and permit sufficient dosing flexibility in patients with ACLF, who are known to have varying degrees of renal or hepatic impairment or failure.
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
globenewswire.com
2025-10-30 16:00:00Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it has given formal notice to the Nasdaq Stock Market of the Company's intention to voluntarily delist its American Depositary Shares (“ADSs”) representing its ordinary shares. Delisting is anticipated to be effective prior to the opening of trading on November 20, 2025, at which time the ADSs will no longer trade on the Nasdaq Global Select Market.
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
globenewswire.com
2025-10-28 17:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025.
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
globenewswire.com
2025-09-22 16:10:00Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 22, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2025 financial results and provided a corporate update.
Wall Street Week Ahead
seekingalpha.com
2025-09-21 06:10:38Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
globenewswire.com
2025-09-19 16:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder).
Genfit assumed with a Buy at H.C. Wainwright
https://thefly.com
2025-08-19 06:05:44H.C. Wainwright assumed coverage of Genfit with a Buy rating and $9 price target. The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
globenewswire.com
2025-07-08 16:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
globenewswire.com
2025-06-17 14:30:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors.
No data to display
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
globenewswire.com
2025-12-10 12:00:00Données préliminaires très encourageantes de l'étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter: Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d'une troisième cohorte de patientsLa combinaison GNS561MEKi a démontré une stabilisation de la maladie chez tous les patients évaluables, avec des signes de réduction tumorale dans un sous-groupe de patients, justifiant la poursuite de l'investigationDoses recommandées pour la Phase 2 attendues au premier semestre 2026 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), le 10 décembre 2025 - GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd'hui des données préliminaires de Phase 1b encourageantes issues de son essai clinique évaluant GNS561 en combinaison dans le CCA.
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
globenewswire.com
2025-12-10 12:00:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today reports encouraging preliminary Phase 1b data from its CCA clinical trial evaluating GNS561 in combination.
GENFIT Announces Appointment of new Chief Medical Officer
globenewswire.com
2025-11-27 12:00:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT's clinical development plans and lead the Clinical (Operations and Strategy), Biometrics and Pharmacovigilance teams.
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
globenewswire.com
2025-11-20 12:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its third quarter 2025 financial results1 and provided a corporate update.
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
globenewswire.com
2025-11-20 12:00:00GENFIT announces the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Selec
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
globenewswire.com
2025-11-10 01:45:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Failure (ACLF) research via exosome-based regenerative technology.
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
globenewswire.com
2025-11-10 01:30:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a novel formulation, investigational drug G1090N, which serves as the cornerstone of our ACLF pipeline and reflects our commitment to addressing critical unmet needs in liver disease. G1090N was designed to optimize dose-response and permit sufficient dosing flexibility in patients with ACLF, who are known to have varying degrees of renal or hepatic impairment or failure.
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
globenewswire.com
2025-10-30 16:00:00Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced it has given formal notice to the Nasdaq Stock Market of the Company's intention to voluntarily delist its American Depositary Shares (“ADSs”) representing its ordinary shares. Delisting is anticipated to be effective prior to the opening of trading on November 20, 2025, at which time the ADSs will no longer trade on the Nasdaq Global Select Market.
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
globenewswire.com
2025-10-28 17:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025.
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
globenewswire.com
2025-09-22 16:10:00Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 22, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2025 financial results and provided a corporate update.
Wall Street Week Ahead
seekingalpha.com
2025-09-21 06:10:38Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
globenewswire.com
2025-09-19 16:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder).
Genfit assumed with a Buy at H.C. Wainwright
https://thefly.com
2025-08-19 06:05:44H.C. Wainwright assumed coverage of Genfit with a Buy rating and $9 price target. The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
globenewswire.com
2025-07-08 16:10:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
globenewswire.com
2025-06-17 14:30:00Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors.